Race-specific differences in endothelial function: Predisposition of African Americans to vascular diseases

Circulation

Volumn 109, Issue 21, 2004, Pages 2511-2517

  Kalinowski, Leszek ^a,b   Dobrucki, Iwona T ^a   Malinski, Tadeusz ^a  

^a OHIO UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

African Americans; Endothelium; Ethnic groups; Nitric oxide; Risk factors

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; ELECTROCHEMISTRY; EUROPEAN AMERICAN; FEMALE; HUMAN; HUMAN CELL; NORMAL HUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ACETOPHENONES; ADULT; AFRICAN AMERICANS; BENZOPYRANS; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MECLOFENAMIC ACID; NAD; NADP; NADPH OXIDASE; NANOTECHNOLOGY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYPURINOL; PEROXYNITROUS ACID; PHOSPHOPROTEINS; ROTENONE; SUPEROXIDES; UMBILICAL VEINS; VASCULAR DISEASES;

EID: 2642527792     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000129087.81352.7A     Document Type: Article

References (23)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
3. Hamilton CA, Brosnan MJ, Al-Benna S, et al. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension. 2002;40:755-762.
4. Raman CS, Li H, Martasek P, et al. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell. 1998;95:939-950.
5. Xia Y, Dawson VL, Dawson TM, et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci U S A. 1996;93:6770-6774.
6. Huk I, Nanobashvili J, Neumayer C, et al. L-Arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation. 1997;96:667-675.
7. Xue J, Ying X, Chen J, et al. Amperometric ultramicrosensors for peroxynitrite detection and its application toward single myocardial cells. Anal Chem. 2000;72:5313-5321.
8. Lvovich V, Scheeline A. Amperometric sensors for simultaneous superoxide and hydrogen peroxide detection. Anal Chem. 1997;69:454-462.
9. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358:676-678.
10. Kalinowski L, Dobrucki LW, Brovkovych V, et al. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002;105:933-938.
11. Vallance P, Patton S, Bhagat K, et al. Direct measurement of nitric oxide in human beings. Lancet. 1995;346:153-154.
12. Bennett JE, Malinski T. Conductive polymeric porphyrin films: application in the electrocatalytic oxidation of hydrazine. Chem Mater. 1991;3:490-495.
13. Holm P, Kankaanranta H, Metsa-Ketela T, et al. Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N-acetylpenicillamine. Eur J Pharmacol. 1998;346:97-102.
14. Cayatte AJ, Rupin A, Oliver-Krasinski J, et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscler Thromb Vasc Biol. 2001;21:1577-1584.
15. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85-E90.
16. Kalinowski L, Dobrucki IT, Malinski T. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol. 2002;53:585-595.
17. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
18. van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192:1731-1744.
19. Patel KB, Stratford MR, Wardman P, et al. Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med. 2002;32:203-211.
20. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43:562-571.
21. Cosentino F, Patton S, d'Uscio LV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest. 1998;101:1530-1537.
22. Cardillo C, Kilcoyne CM, Cannon RO III, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:90-95.
23. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.